Background and Objectives: Hypertension is a widely prevalent con-dition of elevated blood
pressure (BP) and is the leading risk factor for the development of cardiovascular disease …

Background: The antihypertensive activity of beta-blockers generally increases during the
first 6 to 8 weeks of treatment; however, no study has systematically assessed whether blood …

Nebivolol is a novel, β1-adrenergic receptor blocker with vasodilatory properties mediated
through the activation of the l-arginine/nitric oxide pathway. Short-term randomized clinical …

Purpose Our meta-analysis was undertaken to evaluate the efficacy and safety of nebivolol
compared with other second-generation β blockers for hypertensive patients. Methods We …

Background and objective Lowering BP to normal levels without quality of life deterioration
is the most important means of reducing cardiovascular risk. Recent studies have …

Background: Effective blood pressure (BP)-lowering therapy is regarded as the most
important intervention in diabetes mellitus. Nebivolol is commonly used for the treatment of …

This double‐blind, multicenter, randomized placebo‐controlled study evaluated the
antihypertensive efficacy and safety of nebivolol, a selective β1‐adrenoreceptor blocker with …

In order to evaluate the efficacy and tolerability of nebivolol during long term treatment of
outpatients with hypertension, 6 open multicentre studies are being carried out in 5 different …

Background: Nebivolol is a third-generation β1-selective β-blocker that is approved for the
treatment of hypertension. Objective: This article reviews the clinical pharmacology of …

Background. Nebivolol is a highly selective β1-adrenoreceptor antagonist with vasodilating
properties. This study investigated its effect on quality of life (QoL) and blood pressure (BP) …